Home LiteratureArticle Details
PMID: 19690315 Published · ppublish English Comment Editorial

The risks and benefits of HPV vaccination.

JAMA ·Vol. 302 ·No. 7 ·2009-08-19 ·Pages 795-6

Haug C

Abstract

暂无摘要

MeSH Terms
Adverse Drug Reaction Reporting Systems Ethics, Business Female Financial Support Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18 Humans Marketing Papillomavirus Infections/prevention & control Papillomavirus Vaccines/adverse effects Risk Assessment United States Uterine Cervical Neoplasms/prevention & control,virology Vaccination/standards
Chemicals
Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18 Papillomavirus Vaccines
Authors & Affiliations
1 authors, click to expand affiliations / ORCID
Haug Charlotte
Article Info
Journal
JAMA
Abbr.
JAMA
ISSN
1538-3598
DOI
10.1001/jama.2009.1215
Published
2009-08-19
Pages
795-6
Language
English
Region
United States
NLM ID
7501160
Subset
IM
Corrections
CommentOn
PMID: 19690307
CommentOn
PMID: 19690311
CommentIn
PMID: 20040548
CommentIn
PMID: 20040549
External Links
PubMed source DOI: 10.1001/jama.2009.1215 View journal details
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com

Copyright © 2026.Genelibs Jinan Honghui Biotechnology Co., Ltd. 鲁ICP备20007159号-2